ResMed (ASX:RMD) Ending Cash Position: A$2,366 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RMD ResMed Inc ASX:RMD
98 GF Score
Price A$27.43
GF Value A$38.52
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Ending Cash Position?

ResMed ASX:RMD -0.40% 98 Ending Cash Position is A$2,366 Mil as of Mar. 2026. GuruFocus rates ASX:RMD with a GF Score™ of 98/100 and a GF Value™ of A$38.52 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ResMed's Ending Cash Position for the quarter that ended in Mar. 2026 was A$2,366 Mil.

ResMed's quarterly Ending Cash Position increased from Sep. 2025 (A$2,098 Mil) to Dec. 2025 (A$2,133 Mil) and increased from Dec. 2025 (A$2,133 Mil) to Mar. 2026 (A$2,366 Mil).

ResMed's annual Ending Cash Position increased from Jun. 2023 (A$340 Mil) to Jun. 2024 (A$359 Mil) and increased from Jun. 2024 (A$359 Mil) to Jun. 2025 (A$1,858 Mil).

ResMed Ending Cash Position Related Terms

ResMed Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ResMed's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Ending Cash Position Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 386.22 389.49 339.56 358.97 1,857.72

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,480.21 1,857.72 2,097.91 2,132.69 2,366.23
ASX:RMD
98GF Score
ResMed Inc ASX:RMD
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ResMed's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=366.123+1491.592
=1,858

ResMed's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2019.324+346.907
=2,366

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$2,366 Mil mean?
ResMed (ASX:RMD) has a Ending Cash Position of A$2,366 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ResMed and its competitors.
Is ResMed's Ending Cash Position too high?
ResMed's current Ending Cash Position is A$2,366 Mil. Overall, ResMed has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Ending Cash Position compare to MDLN and WST?
ResMed's Ending Cash Position of A$2,366 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ResMed and its competitors. ResMed's current Ending Cash Position is A$2,366 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$38.52, compared to a current price of A$27.43 — trading 28.8% below its estimated fair value. The current Ending Cash Position is A$2,366 Mil. ResMed's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Ending Cash Position is A$2,366 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (ASX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of A$27.43 is trading 28.8% below its estimated GF Value™ of A$38.52. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for ASX:RMD:

  • Ending Cash Position: A$2,366 Mil
  • GF Value™: A$38.52 vs. price of A$27.43 (28.8% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
98GF Score

Get the complete analysis for ASX:RMD

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$27.43
Price
A$38.52
GF Value